TIM22 Complex as a Potential Drug Target and Biomarker (P17900)

Target Name: TIM22 complex

NCBI ID: P17900

TIM22 complex

Other Name(s): TIM22

TIM22 Complex as a Potential Drug Target and Biomarker

TIM22 complex is a protein that plays a crucial role in the regulation of various cellular processes, including cell adhesion, migration, and invasion. The TIM22 complex is composed of Tim22, Tal31, and Calbindin, which are essential for its proper function. This protein complex has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become an attractive target for drug development.

Diseases associated with TIM22 complex

TIM22 complex has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

1. Cancer:

TIM22 is a well-established cancer-associated protein that has been shown to promote the development and progression of various types of cancer. For instance, studies have shown that high expression of TIM22 is associated with poor prognosis in colorectal cancer patients. Additionally, TIM22 has been shown to promote the formation of cancer-invading blood vessels, which can further contribute to tumor progression.

2. Neurodegenerative Diseases:

TIM22 has also been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that TIM22 is expressed in the brains of individuals with Alzheimer's disease and that its levels are decreased in individuals with Parkinson's disease. Additionally, TIM22 has been shown to be involved in the development of neurofibrillary tangles, which are a hallmark of neurodegenerative diseases.

3. Autoimmune Disorders:

TIM22 has also been implicated in the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that TIM22 is expressed in the tissues of individuals with rheumatoid arthritis and that its levels are decreased in individuals with lupus. Additionally, TIM22 has been shown to play a role in the development of multiple sclerosis, an autoimmune disorder that causes muscle weakness and fatigue.

Targeting TIM22

Despite the potential benefits of TIM22 as a drug target, much work remains to be done before it can be effectively targeted. There are several approaches that can be used to target TIM22, including:

1. Small molecule inhibitors:

Small molecules can be used to inhibit the activity of TIM22 by binding to its various subunits. One such approach is the use of inhibitors that target specific subunits of TIM22. For instance, recent studies have shown that inhibitors targeting the protein kinase CK2 (a subunit of TIM22) have the potential to be effective in treating cancer and neurodegenerative diseases.

2. Monoclonal antibodies:

Monoclonal antibodies can be used to target TIM22 by binding to its various subunits. One such approach is the use of antibodies that specifically recognize TIM22. Recent studies have shown that monoclonal antibodies targeting TIM22 have the potential to be effective in treating cancer and neurodegenerative diseases.

3. Peptide-conjugated nanoparticles:

Peptide-conjugated nanoparticles can be used to deliver TIM22 inhibitors to cells in a targeted manner. This approach can be useful for treating diseases where TIM22 is expressed at high levels, such as cancer and neurodegenerative diseases.

Conclusion

In conclusion, TIM22 complex is a protein that has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become an attractive target for drug development. The use of small molecule inhibitors, monoclonal antibodies, and peptide-conjugated nanoparticles can be effective in targeting TIM22 and may lead to the development of new treatments for these diseases. Further research is needed to fully understand the role of TIM22 in disease and to develop effective treatments.

Protein Name: TIM22 Complex

The "TIM22 complex Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TIM22 complex comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets